ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 427

US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs

Grant W. Cannon1, Scott L. DuVall2, Candace L. Hayden3, Liron Caplan4, Jeffrey R. Curtis5, Kaleb Michaud6, Ted R. Mikuls7, Andreas M. Reimold8, David H. Collier9, George Joseph9, David J. Harrison9 and Brian C. Sauer10, 1Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, 2VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 3Epidemiology, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 4Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO, 5Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, 7Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 8Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, 9Amgen Inc., Thousand Oaks, CA, 10Epdemiology, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Adalimumab, etanercept, infliximab, registries and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy I

Session Type: Abstract Submissions (ACR)

Background/Purpose:  While tumor necrosis factor (TNF) blockers can be effective in treating rheumatoid arthritis (RA), the benefit of switching among TNF blockers is not clear.  The objective of this study was to compare clinical outcomes and costs in US veterans who switch between adalimumab (ADA), etanercept (ETN), and infliximab (INF) to patients treated with the same TNF blocker.

Methods:   The Veterans Affairs Rheumatoid Arthritis (VARA) registry is a longitudinal, observational, cohort study of US veterans with RA.  It links to VA pharmacy and administrative data and documents longitudinal assessments of RA disease activity and outcomes.  VARA patients initiating ADA, ETN, or INF from March 2003 (the date after which all agents were available within VA) to Sept 2010 were identified and followed until Sept 2011.  A treatment course was defined as continuous TNF blocker use without a ≥90-day gap in treatment.  The cost of TNF blockers with associated drug administration costs was determined for the first course initiated within the VA and compared to the second course with the same or a different TNF blocker.

Results:  Data from 563 RA patients (204 ADA, 290 ETN, 69 INF) initiating TNF-blocker therapy were analyzed.  All groups had a similar decrease in DAS28 during their first TNF-blocker course; however, baseline DAS28 prior to treatment and during treatment was higher during the first course for patients who eventually switched TNF blocker therapy.  In the 61 patients who had 2 courses of therapy with DAS28 measurements available during both courses of treatment, there were no significant differences between mean DAS28 during the first and second TNF-blocker courses.  Thus, patients who switched TNF-blocker therapies had higher DAS28 prior to and during TNF-blocker treatment compared with patients with a single TNF-blocker course or patients who had 2 courses with the same therapy interrupted by a ≥90-day gap; however, the relative change in DAS28 was the same in all groups during TNF-blocker treatment.  While annualized costs were similar in all groups during the first course of therapy, these costs were significantly higher during the second course in patients who switched than for patients who restarted their initial TNF blocker (P<0.05).

Conclusion: In VARA patients receiving 2 courses of TNF-blocker therapy, improvements in DAS28 scores were not significantly different in patients treated with a different second agent than re-starting the initial agent.  Patients who switched TNF blockers had higher DAS28 scores during the initial course and higher costs overall than patients who remained on the same TNF-blocker therapy.  Because of potential confounding factors inherent in observational studies, more research is needed to understand reasons for switching and the effects of switching TNF blockers on overall outcomes in RA.

Table: Comparison of patients with a single vs a second course with and without switching

 

Single course
(N=264)

Second course,
same TNF blocker
(N=143)

Second course, different TNF blocker (N=156)

 

Mean

95% CI

Mean

95% CI

Mean

95% CI

Age at start of Rx (yrs)

63.1

61.9, 64.3

57.7

55.6, 59.8

59.0

57.5, 60.5

RA disease duration at Rx (yrs)

10.6

9.3, 11.9

10.9

9.1, 12.7

9.9

8.4, 11.3

Male sex, n (%)

234 (89)

(85, 92)

131 (92)

(88, 97)

142 (91)

(87, 96)

First TNF-Blocker Course

 

 

 

 

 

 

  Course duration (mos)

34.1

30.7, 37.5

18.1

15.4, 20.9

18.0

14.9, 21.1

  Annual drug and admin costs (US $ x 1000)

13.8

13.4, 14.2

13.2

12.1, 14.3

14.2

13.4, 14.8

  DAS28 before Rx

4.5

4.3, 4.7

4.6

4.3, 4.9

5.3

5.0, 5.6

  DAS28 after ≥90 days on Rx

3.5

3.3, 3.7

3.5

3.3, 3.8

4.3

4.0, 4.6

  Change in DAS28 on Rx

-0.9

-1.2, -0.7

-1.1

-1.5, -0.6

-0.8

-1.3, -0.4

Second TNF-Blocker Course

 

 

 

 

 

 

  Course duration (mos)

N/A

N/A

15.6

12.8, 18.5

17.7

14.9, 20.5

  Annual drug and admin costs (US $ x 1000)

N/A

N/A

12.9

12.1, 13.6

15.1

13.6, 16.5

  DAS28 after ≥90 days on Rx

N/A

N/A

3.4

3.1, 3.8

4.2

3.9, 4.5

  Change in DAS28 1st to 2nd course

N/A

N/A

-0.2

-0.6, 0.1

-0.2

-0.6, 0.1

CI, confidence interval; Rx, treatment; DAS28, disease activity score based on 28 joints

Sponsored by Immunex, a wholly owned subsidiary of Amgen and by Wyeth.


Disclosure:

G. W. Cannon,

Amgen,

2;

S. L. DuVall,

Anolinx LLC,

2,

Genentech ,

2,

Fa Hoffmann-La Roche Ltd,

2,

Amgen ,

2,

Shire PLC,

2,

Mylan Specialty LP,

2,

Merck and Co., Inc.,

2;

C. L. Hayden,
None;

L. Caplan,
None;

J. R. Curtis,

Roche/Genentech, UCB, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, AbbVie,

2,

Roche/Genentech, UCB, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, AbbVie,

5;

K. Michaud,
None;

T. R. Mikuls,

Roche/Genentech and Biogen IDEC Inc.,

2;

A. M. Reimold,

UCB,

5,

Abbvie,

2;

D. H. Collier,

Amgen Inc.,

1,

Amgen Inc.,

3;

G. Joseph,

Amgen Inc.,

3;

D. J. Harrison,

Amgen Inc.,

1,

Amgen Inc.,

3;

B. C. Sauer,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/us-veterans-with-rheumatoid-arthritis-who-switch-among-tumor-necrosis-factor-blocking-agents-have-no-additional-clinical-benefit-with-the-change-in-therapy-and-incur-higher-costs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology